

APR 11 2000

PATENT #6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Fallaux et al.

Serial No.: 09/332,803

Filed: June 14, 1999

For: PACKAGING SYSTEMS FOR  
HUMAN RECOMBINANT ADENOVIRUS  
TO BE USED IN GENE THERAPY

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 4075US



File Copy

09.1632

Kinda

4/12/00

W/ATTACH

CERTIFICATE OF MAILING

I hereby certify that this paper or fee along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

March 31, 2000  
Date of Deposit

*Lynette Eliason*  
Signature of registered practitioner or other person  
having reasonable basis to expect mailing to occur on  
date of deposit shown pursuant to 37 C.F.R. §  
1.8(a)(1)(ii)

Lynette Eliason  
Typed/printed name of person whose signature is  
contained above

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as

TC 1700 MAIL ROOM

RECEIVED

APR 19 2000

defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

DOCUMENTS

U.S. Patent Documents

U.S. Patent No.	Issue Date	Inventor
92 4,405,712	09/20/83	Vande Woude et al.
4,497,796	02/05/85	Salser et al.
4,727,028	02/23/88	Santerre et al.
4,740,463	04/26/88	Weinberg et al.
5,190,931	03/02/93	Inouye
5,208,149	05/04/93	Inouye
5,518,913	05/21/96	Massie et al.
5,837,511	11/17/98	Falck-Pedersen et al.
5,994,106	11/30/99	Kovesdi et al.
5,994,128	11/30/99	Fallaux et al.
6,033,908	03/07/00	Bout et al.
92 6,040,174	03/21/00	Imler et al.

Foreign Patent Documents

<u>Document No.</u>	<u>Date</u>	<u>Country</u>
CA 2053187	04/11/93	Canada
WO 94/28152	12/08/94	PCT
FR 2707664	01/20/95	France
WO 95/02697	01/26/95	PCT
CA 2117668	09/10/95	Canada
AU-A-28533/95	03/21/96	Australia

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56 & 1.175, applicant hereby identifies the following listed copending applications naming the same inventor(s):

Serial No.: 09/214,836  
 Filed: October 4, 1999  
 For: MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND VACCINES  
 AGAINST MELANOMA

Serial No.: 09/444,284  
 Filed: November 19, 1999  
 For: GENE DELIVERY VECTORS PROVIDED WITH A TISSUE TROPISM FOR  
 SMOOTH MUSCLE CELLS, AND/OR ENDOTHELIAL CELLS

Serial No.: 09/481,201  
 Filed: January 11, 2000  
 For: INTERLEUKIN-3 GENE THERAPY FOR CANCER

Serial No.: 09/506,548  
 Filed: February 17, 2000  
 For: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS TO  
 BE USED IN GENE THERAPY

Serial No.: 09/517,898  
 Filed: March 3, 2000  
 For: MEANS AND METHODS FOR FIBROBLAST-LIKE OR MACROPHAGE-  
 LIKE CELL TRANSFUSION

Considered: David M. ...

This Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required. In the event that a first office action has been mailed, the office is authorized to charge the requisite fee from account no. 20-1469.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Allen C. Turner', with a long horizontal flourish extending to the right.

Allen C. Turner  
Registration No. 33,041  
Attorney for Applicants  
TRASK, BRITT & ROSSA  
P. O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: (801) 532-1922

Date: March 31, 2000

ACT/le

Enclosure: Copy of documents cited  
Form PTO-1449